Cinryze® (C1 esterase inhibitor [human])

Cinryze is covered for HAE prophylaxis (FDA) and for acute HAE treatment (compendial) only for patients with HAE type I or II confirmed by baseline functional C1‑INH <50% of normal and low serum C4 (other causes of angioedema excluded). Coverage requires prescription by or consultation with an allergist/immunologist or HAE specialist, adherence to age/weight dosing limits (adolescents/adults 1,000 IU IV q3–4 days, up to 2,000 IU or 80 IU/kg; children 6–11 500 IU IV q3–4 days, up to 1,000 IU), 12‑month approvals, and reauthorization with documented clinical benefit.

"Prophylaxis against Hereditary Angioedema (HAE) attacks."

Sign up to see full coverage criteria, indications, and limitations.